









Markets
/
Stocks
/
nasdaq-vani
/

Vivani Medical Inc

VANI

1.505USD

-0.095-5.94%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

89.16MMarket Cap

LossP/E TTM



Vivani Medical Inc

1.505

-0.095-5.94%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Vivani Medical Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Vivani Medical Inc's Score

Industry at a Glance

Industry Ranking

124 / 210

Overall Ranking

266 / 4617

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

5.000

Target Price

+210.56%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Vivani Medical Inc Highlights

StrengthsRisks

Vivani Medical, Inc. is a biopharmaceutical company developing novel, ultra-long-acting drug implants. Leveraging its NanoPortal platform, the Company develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Its lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of chronic weight management in obese or overweight individuals. Its pipeline also includes the NPM-139 (semaglutide) implant which is also under development for chronic weight management in obese and overweight individuals. NPM-119 refers to its Type II diabetes development program. OKV-119 is an exenatide implant that is under development for metabolic diseases in cats, including for the treatment of obesity and diabetes. Its segments include Biopharm Division and Neurostimulation Division.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -3.62, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 4.05M shares, decreasing 17.04% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.43M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 5.69, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.69

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

4.92

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.55

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

5.00

Key Metrics

Free cash flow

No Data

Vivani Medical Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 7.34, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -3.62, which is -58.70% below the recent high of -1.50 and -130.90% above the recent low of -8.37.

Score

Industry at a Glance

Previous score

7.34

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 124/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Vivani Medical Inc is 4.00, with a high of 7.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

5.000

Target Price

+212.50%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

110

Total

Median

Average

Company name

Ratings

Analysts

Vivani Medical Inc

VANI

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 7.38, which is higher than the Healthcare Equipment & Supplies industry's average of 6.72. Sideways: Currently, the stock price is trading between the resistance level at 1.91 and the support level at 1.30, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.39

Change

-0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.029

Neutral

RSI(14)

47.518

Neutral

STOCH(KDJ)(9,3,3)

17.862

Sell

ATR(14)

0.163

Low Volatility

CCI(14)

-115.380

Sell

Williams %R

72.807

Sell

TRIX(12,20)

0.772

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.635

Sell

MA10

1.639

Sell

MA20

1.563

Sell

MA50

1.427

Buy

MA100

1.387

Buy

MA200

1.245

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 6.84%, representing a quarter-over-quarter decrease of 87.94%. The largest institutional shareholder is The Vanguard, holding a total of 1.43M shares, representing 2.42% of shares outstanding, with 48.06% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Williams (Gregg)

18.29M

+0.58%

Bolck (Joachim Eberhard)

5.60M

Mendelsohn (Adam)

3.75M

+1.58%

The Vanguard Group, Inc.

Star Investors

1.43M

+48.09%

Mendelsohn (Aaron)

1.09M

Tanager Wealth Management LLP

1.02M

-16.56%

Geode Capital Management, L.L.C.

353.90K

-1.84%

Commonwealth Financial Network

330.53K

Baker (Wilford Dean)

197.48K

Monetary Management Group, Inc.

193.98K

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 2.54, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 3.15. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.